One-year surgical outcomes of the PreserFlo MicroShunt in glaucoma: a multicentre analysis

Conclusion
The PreserFlo MicroShunt with MMC 0.4 mg/mL showed an overall success rate of 68.3% at 1 year, and led to significant IOP and medication reduction with a low rate of adverse effects.

Source: British Journal of Ophthalmology - July 20, 2023 Category: Opthalmology Authors: Tanner, A., Haddad, F., Fajardo-Sanchez, J., Nguyen, E., Thong, K. X., Ah-Moye, S., Perl, N., Abu-Bakra, M., Kulkarni, A., Trikha, S., Lascaratos, G., Parnell, M., Kailani, O., King, A. J., Agrawal, P., Stead, R., Giannouladis, K., Rodrigues, I., Goyal, S Tags: Open access Original articles - Clinical science Source Type: research